MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c · MRWQEMGYIFYPRKLR · ~2174 Da (16 amino acids)
Executive Summary
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA, with translation proposed to occur in the cytoplasm from a polyadenylated transcript exported from mitochondria. The most robust experimental evidence base is preclinical: in cell systems and multiple mouse models, MOTS-c influences metabolic pathways linked to the folate-purine axis and AMPK activation, improves insulin sensitivity, reduces diet-induced obesity in some models, and can enhance treadmill/rotarod performance in mice. Human evidence does not currently establish MOTS-c as a therapy. Published human work is largely observational/associational (exercise-linked changes, age-linked differences in plasma vs muscle, cross-sectional disease associations), plus one large genetic association analysis of an mtDNA variant affecting the peptide sequence. These data are biologically interesting but not equivalent to clinical efficacy or safety evidence for administered MOTS-c. From a regulatory and safety standpoint, the most concrete official signals are cautionary: the U.S. FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, flagging potential immunogenicity/impurity and lack of identified human exposure data. WADA explicitly lists MOTS-c as an example under AMPK activators (S4.4.1), meaning it is prohibited in sport.
MOTS-c is preclinical-promising with genuinely interesting mechanistic biology and strong mouse metabolic data, but it is clinically unproven in humans; observational human evidence is hypothesis-generating, not prescribing data; and regulatory/safety flags from FDA and WADA should not be downplayed.
What MOTS-c Is and What It Is Not
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded by a 51-bp short open reading frame in mitochondrial 12S rRNA. The foundational research argues that translation obligatorily occurs in the cytoplasm using the standard genetic code because mitochondrial translation would yield tandem start/stop codons, implying a polyadenylated transcript exported from mitochondria. It was first described in a 2015 foundational report that identified this mitochondrial-derived peptide and characterised its metabolic effects in cell systems and mouse models.
- It is not an approved therapeutic drug for any indication by any major regulator, and should not be described as a clinically validated therapy.
- It is not supported by any published controlled human trials demonstrating efficacy for metabolism, exercise performance, longevity, or any other common marketing claim.
- It is not 'clearly safe' for human use: the FDA explicitly flags immunogenicity/impurity risks and lack of identified human exposure data for compounded MOTS-c products.
- 'Mitochondrial-encoded' does not mean 'mitochondrially translated.' The central peer-reviewed claim is that the coding sequence is mitochondrial, while translation is proposed to occur in the cytoplasm.
Mechanism of Action
Folate-purine axis and AMPK activation
Supported in cell and mouse modelsThe most specific mechanistic pathway involves metabolic modulation through the folate-methionine cycle. In MOTS-c gain-of-function systems, metabolomics and transcriptomics showed early changes including decreased 5-methyl-THF, evidence consistent with blockade of de novo purine synthesis, and endogenous AICAR accumulation to >20-fold higher levels versus controls. AMPK phosphorylation (Thr172) increased with downstream ACC phosphorylation and CPT-1 changes, consistent with AMPK pathway activation. In mice, this translated to improved insulin sensitivity (including gold-standard clamp-based measures) and reduced diet-induced obesity signals.
The AMPK story is real in the mechanistic papers, but it is built on particular experimental contexts (cell lines, overexpression systems, micromolar peptide exposures, and mouse intraperitoneal injections). Translating 'activates AMPK' into guaranteed human fat loss, longevity, or metabolic reset is not supported by human interventional evidence.
Nuclear translocation and ARE/NRF2-linked gene regulation
Demonstrated in cell models under stressUnder metabolic stress (glucose restriction 0.5 g/L, serum deprivation 1% FBS, oxidative stress tBHP 100 uM), endogenous MOTS-c rapidly translocated to the nucleus in cell models. FITC-labelled MOTS-c (1 uM) localised to mitochondria and nucleus within 30 minutes in HEK293 cells. The research reports direct DNA binding to ARE-containing promoter fragments (e.g., HO-1, NQO1) in concentration-dependent EMSA experiments, plus stress-linked ChIP-qPCR evidence of promoter association and NRF2-linked transcriptional effects. RNA-seq supported the claim that MOTS-c can alter gene expression responses to glucose restriction in that cellular context.
If discussing gene modulation, anchor it here: nucleocytoplasmic localisation under defined stressors, and specific ARE/NRF2-linked assays in cell systems. Broad marketing claims like 'systemic regeneration,' 'turns on youth genes,' or inevitable nuclear reprogramming in humans are not demonstrated.
Animal Evidence Map
The preclinical literature contains many positive findings, summarised below with stated limitations.
| Domain | Species | Dose | Outcome | Limitation |
|---|---|---|---|---|
| Acute metabolic effects (normal diet) | Mouse (CD-1) | 5 mg/kg/day BID x 4 days, IP | Modest reductions in body weight, food intake, and blood glucose; some inflammatory cytokines (IL-6, TNF-alpha) reduced | Short duration; acute physiology does not equal sustained clinical effect. |
| Insulin sensitivity (clamp studies) | Mouse (C57BL/6) | 5 mg/kg/day IP x 7 days | Improved glucose clearance and clamp-based measures of insulin sensitivity, including skeletal muscle glucose disposal | Short duration; mouse dosing/exposure equivalence unknown for humans. |
| Diet-induced obesity prevention | Mouse (CD-1, HFD) | 0.5 mg/kg/day IP, up to 8 weeks | Prevented diet-induced obesity and hyperinsulinaemia; signals consistent with increased energy expenditure and altered substrate utilisation | Preventive model, not a therapeutic trial; does not predict human weight loss outcomes. |
| Exercise performance (young mice) | Mouse (CD-1) | 5 mg/kg/day IP x 2 weeks (and 5 vs 15 mg/kg/day comparisons) | Improved rotarod performance and treadmill running capacity | Performance tests can be sensitive to multiple factors; not a human trial. |
| Exercise performance (aged mice) | Mouse (C57BL/6N, 12-month and 22-month) | 15 mg/kg/day IP x 2 weeks | Improved treadmill performance in middle-aged and old mice | Short intervention; age-related mouse performance improvement does not equal human anti-ageing proof. |
| Late-life intermittent dosing (lifespan) | Mouse (C57BL/6N, very old) | 15 mg/kg/day, 3x/week (late-life intermittent) | Improved physical function measures; lifespan trend reported but overall curve not significant (P=0.23); time-bounded significance point (P=0.05 until 31.8 months) | Single study; lifespan statistics not uniformly significant; cannot claim proven life extension. |
| Diabetes model (NOD mice) | Mouse (NOD) | 0.5 mg/kg/day IP | Reduced islet/beta-cell senescence signals in diabetes-relevant model | Autoimmune model; not proof of human efficacy or safety. |
| Tissue distribution (mdx mice) | Mouse (mdx) | 500 ug IV (single injection, rhodamine-labelled); repeated 500 ug with PMO regimens | Tissue distribution assessed; improved dystrophin expression with combination; no detectable toxicity in measured endpoints | Disease-specific context; dosing not expressed per kg; combination confounding. |
Human Evidence
Every published human study for MOTS-c is reviewed below. None are randomised controlled trials.
Exercise biomarker study (healthy young men)
Observational biomarker studySmall sample (n=10); measures endogenous biomarker response, not exogenous administration; does not demonstrate that giving MOTS-c improves human exercise capacity.
Supports MOTS-c as an exercise-responsive biomarker, not as an exercise-enhancing therapy.Ageing biomarker divergence study
Cross-sectional observationalCross-sectional design; cannot establish causation; age-related patterns do not prove that supplementing MOTS-c reverses ageing.
Biologically interesting age-related pattern; not evidence for exogenous MOTS-c therapy.Genetic variant K14Q and T2D association
Genetic association meta-analysisGenetic association, not interventional. Does not constitute evidence that exogenous MOTS-c is a safe or effective treatment.
Credible human-relevant evidence for natural variation and disease risk, but not treatment proof.T2D circulating levels cross-sectional comparison
Cross-sectional observationalAssociational only; lower levels could be cause, consequence, or correlated marker. Does not justify clinical claims for administered MOTS-c.
Associational finding; not evidence for MOTS-c as a diabetes treatment.CohBar CB4211 Phase 1a/1b (MOTS-c analogue)
Registered Phase 1a/1b RCT (NCT03998514)Registered trial without posted results or peer-reviewed publication of clinical outcomes. The existence of a registry entry is not evidence of an effective therapy.
Evidence of investigation only. No posted results.Hype vs Evidence
Common online claims compared against what the published evidence actually supports.
| Claim | Social Media Implies | Evidence Supports | Verdict |
|---|---|---|---|
| MOTS-c is an exercise mimetic that boosts performance | Taking MOTS-c replaces exercise or dramatically enhances athletic performance | In mice, MOTS-c improved treadmill/rotarod outcomes under certain dosing regimens. In humans, exercise increases endogenous MOTS-c in muscle and circulation (n=10). No controlled human studies show improved VO2max, endurance, or strength from administered MOTS-c. |
Preclinical signal only; prohibited in sport
|
| It melts fat / fixes insulin resistance | Reliable human weight loss and metabolic improvement from injecting MOTS-c | In mice, improved insulin sensitivity (gold-standard clamp data) and reduced diet-induced obesity signals. No human efficacy trials of administered MOTS-c exist. Cross-sectional human observations are not treatment proof. FDA highlights safety uncertainties for compounded MOTS-c. |
Strong preclinical; no human proof
|
| It reprogrammes genes / activates longevity pathways | Systemic gene reprogramming and rejuvenation in humans | Cell studies show nuclear translocation under stress, RNA-seq changes, and ARE/NRF2-linked promoter interactions. Gene-expression modulation in vitro does not equal systemic reprogramming in humans. No validated human transcriptional endpoints tied to clinical benefit from dosing. |
In vitro biology, not human proof
|
| It extends lifespan | Proven life extension in animals and humans | One mouse study reported healthspan improvements and a lifespan trend under late-life intermittent dosing, but the overall lifespan curve was not statistically significant (P=0.23). No human longevity data exist. |
Trend, not established life extension
|
| Safe for self-use because it's natural/mitochondrial | Endogenous origin means it is inherently safe to inject | Some animal studies report no detectable toxicity under measured endpoints. FDA flags immunogenicity and impurity/characterisation risks for compounded MOTS-c and notes lack of identified human exposure data. No comprehensive human safety datasets exist. |
Unsupported; safety is unknown in humans
|
Evidence Strength Ratings
Each domain rated on a 0-5 scale based on quality and quantity of available evidence.
Safety, Side Effects & Regulatory Status
No human pharmacokinetics or ADME data have been published for native MOTS-c. The CohBar CB4211 analogue Phase 1a/1b programme (NCT03998514) was designed to measure PK/PD, but results have not been posted in the public record. In mouse studies, MOTS-c has been administered intraperitoneally at doses ranging from 0.5 to 15 mg/kg/day, with metabolic and performance effects observed, but exposure-response relationships and bioavailability in humans are entirely unknown. Without human PK data, any dosing recommendations found online are not evidence-based.
The honest safety summary is 'unknown in humans' with official concern signals around compounding, impurity, and immunogenicity. The peer-reviewed animal literature includes instances where authors report no detectable toxicity under measured endpoints, but this is not equivalent to comprehensive toxicology (reproductive toxicology, carcinogenicity, immunogenicity, long-term endocrine effects) and is not equivalent to human safety. No controlled human administration studies with safety monitoring have published results.
FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, flagging potential immunogenicity risk for certain administration routes, complexities in peptide-related impurities and API characterisation, and states it has not identified human exposure data for compounded MOTS-c products and lacks important safety information.
View Official Source →WADA explicitly lists 'mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)' as an example under AMPK activators (S4.4.1), making it prohibited in sport under the category of hormone and metabolic modulators.
View Official Source →What We Still Don't Know
- No controlled human trials administering MOTS-c with clinically meaningful endpoints (metabolic health, functional capacity, ageing outcomes).
- No human pharmacokinetics/ADME for native MOTS-c, including exposure-response relationships, immunogenicity monitoring, and interaction profiling.
- No comprehensive safety datasets beyond limited animal endpoints and beyond non-peer-reviewed reporting.
- Harmonised mechanistic understanding across models (folate-purine axis vs nuclear stress signalling vs muscle stress adaptation) is lacking: which pathways matter in vivo and for which phenotypes remains unresolved.
- The CohBar CB4211 analogue programme (NCT03998514) has not posted results; unpublished industry data, proprietary toxicology, and unposted trial results may exist but cannot be treated as evidence.
References
All primary sources cited in this review. Links open in new tabs.
-
MOTS-c foundational report: metabolic effects of a mitochondrial-derived peptideFirst description of MOTS-c as a 16-amino-acid mitochondrial-derived peptide with metabolic effects including AMPK activation, improved insulin sensitivity, and prevention of diet-induced obesity in mice
-
MOTS-c insulin sensitivity clamp studies in miceGold-standard clamp-based demonstration of improved insulin sensitivity and skeletal muscle glucose disposal with MOTS-c 5 mg/kg/day IP in C57BL/6 mice
-
MOTS-c nuclear translocation and ARE/NRF2 gene regulation under stressDemonstrated stress-responsive nuclear translocation of MOTS-c with direct ARE-containing promoter binding, NRF2-linked transcriptional effects, and RNA-seq validation in cell models
-
MOTS-c physical performance and late-life regimen in miceImproved treadmill/rotarod performance in young, middle-aged, and old mice with MOTS-c; late-life intermittent dosing improved healthspan measures with a lifespan trend
-
Exercise increases skeletal muscle and circulating MOTS-c in humansObservational study in 10 healthy young men showing exercise-induced increases in muscle MOTS-c (~11.9-fold) and circulating MOTS-c (~1.6-fold) during stationary bicycle exercise
-
MOTS-c age-related patterns in human muscle and circulationCross-sectional study showing circulating MOTS-c decreases with age while skeletal muscle expression increases; associations with muscle fibre composition and quality
-
MOTS-c K14Q variant (m.1382A>C) and T2D risk in 27,527 participantsMeta-analysis across three cohorts showing men with the K14Q variant had higher T2D prevalence, with gene-physical activity interaction in the lowest activity tertile
-
MOTS-c and islet senescence in diabetes modelsReduced islet/beta-cell senescence in mouse diabetes models (S961, NOD) with MOTS-c; cross-sectional human comparison showing lower circulating MOTS-c in T2D vs controls
-
MOTS-c tissue distribution and dystrophin enhancement in mdx miceSingle IV injection rhodamine-labelled MOTS-c tissue distribution study; repeated dosing with PMO improved dystrophin expression in mdx dystrophic mice
-
CohBar CB4211 Phase 1a/1b (MOTS-c analogue) registryRegistered randomised placebo-controlled Phase 1a/1b study of MOTS-c analogue CB4211 in healthy volunteers and NAFLD participants; no results posted
Frequently Asked Questions About MOTS-c
MOTS-c has strong preclinical evidence in mouse models for metabolic improvements (insulin sensitivity, reduced diet-induced obesity) and exercise performance enhancement. However, no controlled human trials have been conducted with administered MOTS-c. Human evidence is limited to observational biomarker studies and genetic associations. The overall evidence score is 1.5 out of 5.
Safety in humans is unknown. The U.S. FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, citing potential immunogenicity, peptide impurity concerns, and lack of identified human exposure data. No comprehensive human safety datasets exist for administered MOTS-c.
No human side effect profile has been established because no controlled human trials of administered MOTS-c have been completed and published. Some animal studies report no detectable toxicity within their measured endpoints, but this is not equivalent to comprehensive toxicology or human safety data.
In mice, MOTS-c improved treadmill and rotarod performance under certain dosing regimens. In humans, exercise increases endogenous MOTS-c in muscle and circulation (n=10 study). However, no controlled human studies show that administering MOTS-c improves VO2max, endurance, strength, or functional capacity. MOTS-c is prohibited in sport by WADA as an AMPK activator.
MOTS-c is not an approved human medicine by any major regulator. WADA explicitly lists MOTS-c as an example under AMPK activators (S4.4.1), making it prohibited in sport. The U.S. FDA flags compounded MOTS-c products as potentially presenting significant safety risks. Legal status varies by jurisdiction.
Two core mechanisms are supported by peer-reviewed evidence: (1) metabolic modulation through the folate-purine axis, where MOTS-c depletes folate cycle intermediates, reduces de novo purine synthesis, accumulates AICAR (>20-fold in cell models), and activates AMPK; and (2) stress-responsive nuclear translocation, where MOTS-c enters the nucleus under metabolic stress and regulates gene expression through ARE/NRF2-linked programmes.
One mouse study reported improved physical function measures (healthspan) with late-life intermittent MOTS-c dosing and a lifespan trend, but the overall lifespan curve was not statistically significant (P=0.23). No human longevity data exist. It is not fair to claim proven life extension based on current evidence.
Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026